TrialJournal of the Pediatric Infectious Diseases Society2023

Immunogenicity and Safety of a Third COVID-19 BNT162b2 mRNA Vaccine Dose in 5- to 11-Year Olds.

Eric A F Simões et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.